Author

J. P. Castano

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Organism:human· 3 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

R. M. Luque· 3 shared A. C. Fuentes-Fayos· 2 shared A. Ibanez-Costa· 2 shared E. Alors-Perez· 2 shared M. D. Gahete· 2 shared R. Blazquez-Encinas· 2 shared S. Pedraza-Arevalo· 2 shared A. Arjona-Sanchez· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. M. Luque

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivDec 7, 2023

The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in Pancreatic Ductal Adenocarcinoma

R. Blazquez-Encinas, E. Alors-Perez, M. T. Moreno-Montilla…·J. P. Castano

This study identifies EIF4A3 as an oncogenic factor in PDAC by showing its overexpression correlates with poor prognosis and its role in regulating RNA splicing and tumor growth.

DOI 10.1038/s41417-024-00814-3

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 9, 2022

Spliceosomic dysregulation unveils NOVA1 as an actionable therapeutic target in pancreatic neuroendocrine tumors

S. Pedraza-Arevalo, E. Alors-Perez, R. Blazquez-Encinas…·J. P. Castano

The paper identifies NOVA1 as a therapeutic target in PanNETs by showing its role in splicing dysregulation, cell proliferation, and drug resistance.

DOI 10.1101/2022.02.09.479525

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 13, 2021

A convergent malignant phenotype in B-cell acute lymphoblastic leukemia involving the splicing factor SRRM1

A. Closa, M. Reixachs-Sole, A. C. Fuentes-Fayos…·E. Eyras

The paper identifies a convergent malignant phenotype in infant B-ALL linked to SRRM1 upregulation and splicing alterations, independent of gene fusions.

DOI 10.1101/2021.12.13.472370

humanbulk RNA-seq

𝕏 PostBluesky